Serological Response to Retreatment of Serofast Early Syphilis Cases With Benzathine Penicillin
Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Aug 29, 2016
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Early Syphilis Cases Determined to Be Serofast at 6 Months after Initial Treatment
- Exclusion Criteria:
- • Human immunodeficiency virus (HIV)-infected
- • Baseline serology showed a nonreactive RPR test
- • follow-up is inadequate
- • Allergic to penicillin
- • Pregnant woman
About Peking Union Medical College Hospital
Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials